Effect of c-Met inhibitor SU11274 on human colon cancer cell growth

Chin Med J (Engl). 2013 Jul;126(14):2705-9.

Abstract

Background: Colon cancer is one of the major malignancies worldwide and it still remains resistant to much of the currently available chemotherapy. Downregulation of HGF/c-Met signaling pathway is an emerging therapy for cancer treatment.

Methods: In this study, the inhibitory effects of c-Met phosphorylation were observed with SU11274 on different colon cancer cell lines in vitro.

Results: The results revealed the significant inhibitory effects of SU11274 on cell proliferation and cell survival, in a time and dose-dependent manner. Furthermore, the inhibitory effects of SU11274 on different subgroups of colon cancer cells via the HGF/c-Met signaling pathway were implicated in this study.

Conclusion: The results suggested the possible selective therapeutic effects of c-Met inhibitor on colon cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Hepatocyte Growth Factor / pharmacology
  • Humans
  • Indoles / pharmacology*
  • Piperazines / pharmacology*
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-met / physiology
  • Signal Transduction
  • Sulfonamides / pharmacology*

Substances

  • ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
  • Indoles
  • Piperazines
  • Sulfonamides
  • Hepatocyte Growth Factor
  • Proto-Oncogene Proteins c-met